nf639 Search Results


95
ATCC s aureus ccarm 3090 mrsa
S Aureus Ccarm 3090 Mrsa, supplied by ATCC, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/s aureus ccarm 3090 mrsa/product/ATCC
Average 95 stars, based on 1 article reviews
s aureus ccarm 3090 mrsa - by Bioz Stars, 2026-03
95/100 stars
  Buy from Supplier

90
Charles River Laboratories nf639 cells
(A) Subcutaneous xenografts of <t>NF639</t> breast cancer cells were injected once daily with 10 micrograms rLOX-PP for 5 days beginning on day 17 (arrows). Tumor volumes were monitored by caliper measurements (n = 10; *, p<0.05); (B) The tumor growth rates were determined from measurements made beginning on day 18 and were derived from linear regression analyses of the data. (C) Tumor weights at sacrifice on day 25 (p = 0.4, n = 10).
Nf639 Cells, supplied by Charles River Laboratories, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/nf639 cells/product/Charles River Laboratories
Average 90 stars, based on 1 article reviews
nf639 cells - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

Image Search Results


(A) Subcutaneous xenografts of NF639 breast cancer cells were injected once daily with 10 micrograms rLOX-PP for 5 days beginning on day 17 (arrows). Tumor volumes were monitored by caliper measurements (n = 10; *, p<0.05); (B) The tumor growth rates were determined from measurements made beginning on day 18 and were derived from linear regression analyses of the data. (C) Tumor weights at sacrifice on day 25 (p = 0.4, n = 10).

Journal: PLoS ONE

Article Title: Recombinant Lysyl Oxidase Propeptide Protein Inhibits Growth and Promotes Apoptosis of Pre-Existing Murine Breast Cancer Xenografts

doi: 10.1371/journal.pone.0031188

Figure Lengend Snippet: (A) Subcutaneous xenografts of NF639 breast cancer cells were injected once daily with 10 micrograms rLOX-PP for 5 days beginning on day 17 (arrows). Tumor volumes were monitored by caliper measurements (n = 10; *, p<0.05); (B) The tumor growth rates were determined from measurements made beginning on day 18 and were derived from linear regression analyses of the data. (C) Tumor weights at sacrifice on day 25 (p = 0.4, n = 10).

Article Snippet: NF639 cells (4×10 6 cells) were injected subcutaneously into the midline dorsa (n = 10/condition) of NCR nu/nu mice (Charles River Laboratories), and tumors allowed to grow to 100 mm 3 .

Techniques: Injection, Derivative Assay

(A) Subcutaneous 100 mm 3 xenografts of NF639 breast cancer cells were established in mice. rLOX-PP/alginate or empty beads were implanted on day 15 (arrow). Tumors were monitored by caliper measurements (n = 10; *, p<0.05, ***, p<0.01). (B) The tumor growth rates were determined from measurements made beginning on day 18 and were derived from linear regression analyses of the data; (C) tumor weights determined at sacrifice on day 25 (n = 10; *, p<0.05).

Journal: PLoS ONE

Article Title: Recombinant Lysyl Oxidase Propeptide Protein Inhibits Growth and Promotes Apoptosis of Pre-Existing Murine Breast Cancer Xenografts

doi: 10.1371/journal.pone.0031188

Figure Lengend Snippet: (A) Subcutaneous 100 mm 3 xenografts of NF639 breast cancer cells were established in mice. rLOX-PP/alginate or empty beads were implanted on day 15 (arrow). Tumors were monitored by caliper measurements (n = 10; *, p<0.05, ***, p<0.01). (B) The tumor growth rates were determined from measurements made beginning on day 18 and were derived from linear regression analyses of the data; (C) tumor weights determined at sacrifice on day 25 (n = 10; *, p<0.05).

Article Snippet: NF639 cells (4×10 6 cells) were injected subcutaneously into the midline dorsa (n = 10/condition) of NCR nu/nu mice (Charles River Laboratories), and tumors allowed to grow to 100 mm 3 .

Techniques: Derivative Assay